IL-17RA Antibody
| Code | Size | Price |
|---|
| PSI-7419-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-7419-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
IL-17RA Antibody: CD217, IL17R, CANDF5, CDw217, IL-17RA, hIL-17R, Interleukin-17 receptor A, IL-17 receptor A
Application Note:
IL-17RA antibody can be used for detection of IL-17RA by Western blot at 1 - 2 μg/mL.
Antibody validated: Western Blot in mouse samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in mouse samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
IL-17RA Antibody: Interleukin 17A (IL-17A) is a proinflammatory cytokine secreted by activated T-lymphocytes (1). It is a potent inducer of the maturation of CD34-positive hematopoietic precursors into neutrophils. IL-17RA is a ubiquitous type I membrane glycoprotein that binds with low affinity to IL-17A and IL-17F (1,2). IL-17A and its receptor play a pathogenic role in many inflammatory and autoimmune diseases such as rheumatoid arthritis (3,4). Defects in IL-17RA are the cause of familial candidiasis type 5 (CANDF5) which is a rare disorder with altered immune responses and impaired clearance of fungal infections (5).
Background References:
- Yao Z, Painter SL, Fanslow WC, et al. Human IL-17: a novel cytokine derived from T cells. J. Immunol. 1995; 155: 5483-6.
- Yao Z, Fanslow WC, Seldin MF, et al. Herpesvirus saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 1995; 3:811-21.
- Rickel EA, Siegel LA, Yoon BR, et al. Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities. J. Immunol. 2008;181:4299-310.
- Wang M, Wang L, Ren T, et al. IL-17A/IL-17RA interaction promoted metastasis of osteosarcoma cells. Cancer Biol. Ther. 2012;14(2).
Buffer:
IL-17RA Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
IL-17RA antibody was raised against an 18 amino acid peptide near the amino terminus of human IL-17RA.
The immunogen is located within amino acids 150 - 200 of IL-17RA.
The immunogen is located within amino acids 150 - 200 of IL-17RA.
Molecular Weight Explanation:
Other IL-17RA antibodies show similar size band
NCBI Gene ID #:
23765
NCBI Official Name:
interleukin 17 receptor A
NCBI Official Symbol:
IL17RA
NCBI Organism:
homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 95 kDa
Observed: 135 kDa
Observed: 135 kDa
Protein Accession #:
NP_055154
Protein GI Number:
23238208
Purification:
IL-17RA Antibody is affinity chromatography purified via peptide column.
Research Area:
Immunology
SPECIFICITY:
IL-17RA antibody is human, mouse and rat reactive. Multiple isoforms of IL-17RA are known to exist. This antibody is predicted to not cross-react with other IL-17 receptor subunits.
Swissprot #:
Q96F46
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | IL-17RA Peptide | PSI-7419P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|